La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Universal Scientific Industrial (Shanghai) Croissance future
Future contrôle des critères 2/6
Universal Scientific Industrial (Shanghai) is forecast to grow earnings and revenue by 21.7% and 11.4% per annum respectively. EPS is expected to grow by 21.3% per annum. Return on equity is forecast to be 14.6% in 3 years.
Informations clés
21.7%
Taux de croissance des bénéfices
21.3%
Taux de croissance du BPA
| Electronic croissance des bénéfices | 27.3% |
| Taux de croissance des recettes | 11.4% |
| Rendement futur des capitaux propres | 14.6% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 26 Jul 2024 |
Mises à jour récentes de la croissance future
Results: Universal Scientific Industrial (Shanghai) Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 28
Earnings Miss: Universal Scientific Industrial (Shanghai) Co., Ltd. Missed EPS By 7.3% And Analysts Are Revising Their Forecasts
Apr 04Recent updates
Universal Scientific Industrial (Shanghai) Co., Ltd. (SHSE:601231) Looks Inexpensive But Perhaps Not Attractive Enough
Aug 19Results: Universal Scientific Industrial (Shanghai) Co., Ltd. Exceeded Expectations And The Consensus Has Updated Its Estimates
Jul 28Does Universal Scientific Industrial (Shanghai) (SHSE:601231) Have A Healthy Balance Sheet?
Jul 16Universal Scientific Industrial (Shanghai)'s (SHSE:601231) Dividend Is Being Reduced To CN¥0.27
Jun 02Returns On Capital Signal Tricky Times Ahead For Universal Scientific Industrial (Shanghai) (SHSE:601231)
May 21Some Investors May Be Willing To Look Past Universal Scientific Industrial (Shanghai)'s (SHSE:601231) Soft Earnings
Apr 08Earnings Miss: Universal Scientific Industrial (Shanghai) Co., Ltd. Missed EPS By 7.3% And Analysts Are Revising Their Forecasts
Apr 04Universal Scientific Industrial (Shanghai) Co., Ltd. (SHSE:601231) Stock Catapults 27% Though Its Price And Business Still Lag The Market
Mar 04Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2026 | 80,810 | 3,384 | 3,166 | N/A | 6 |
| 12/31/2025 | 73,447 | 2,741 | 2,156 | N/A | 7 |
| 12/31/2024 | 64,276 | 2,238 | 996 | N/A | 5 |
| 6/30/2024 | 61,312 | 1,965 | N/A | N/A | N/A |
| 3/31/2024 | 61,286 | 2,005 | 3,877 | 5,424 | N/A |
| 12/31/2023 | 60,792 | 1,948 | 5,274 | 6,823 | N/A |
| 9/30/2023 | 62,043 | 2,281 | 4,819 | 6,410 | N/A |
| 6/30/2023 | 66,441 | 2,743 | 5,628 | 7,149 | N/A |
| 3/31/2023 | 67,561 | 2,898 | 2,776 | 4,287 | N/A |
| 12/31/2022 | 68,516 | 3,060 | 1,764 | 3,435 | N/A |
| 9/30/2022 | 68,312 | 2,906 | 372 | 1,907 | N/A |
| 6/30/2022 | 61,967 | 2,392 | -2,132 | -433 | N/A |
| 3/31/2022 | 58,319 | 2,052 | -1,011 | 809 | N/A |
| 12/31/2021 | 55,300 | 1,858 | -2,617 | -1,102 | N/A |
| 9/30/2021 | 54,735 | 1,861 | -1,425 | -186 | N/A |
| 6/30/2021 | 52,952 | 1,785 | -453 | 690 | N/A |
| 3/31/2021 | 51,018 | 1,793 | -254 | 891 | N/A |
| 12/31/2020 | 47,696 | 1,739 | 380 | 1,437 | N/A |
| 9/30/2020 | 40,712 | 1,402 | 627 | 1,862 | N/A |
| 6/30/2020 | 39,617 | 1,378 | 974 | 2,011 | N/A |
| 3/31/2020 | 37,142 | 1,230 | 1,113 | 1,870 | N/A |
| 12/31/2019 | 37,204 | 1,262 | 1,752 | 2,426 | N/A |
| 9/30/2019 | 37,375 | 1,263 | -428 | 194 | N/A |
| 6/30/2019 | 35,350 | 1,177 | -264 | 290 | N/A |
| 3/31/2019 | 34,999 | 1,216 | -385 | 150 | N/A |
| 12/31/2018 | 33,550 | 1,180 | -719 | -219 | N/A |
| 9/30/2018 | 31,663 | 1,229 | -88 | 344 | N/A |
| 6/30/2018 | 29,619 | 1,150 | 169 | 510 | N/A |
| 3/31/2018 | 29,462 | 1,214 | N/A | 1,033 | N/A |
| 12/31/2017 | 29,706 | 1,314 | N/A | 1,239 | N/A |
| 9/30/2017 | 27,689 | 1,136 | N/A | 1,744 | N/A |
| 6/30/2017 | 26,950 | 1,097 | N/A | 1,587 | N/A |
| 3/31/2017 | 25,552 | 1,008 | N/A | 2,055 | N/A |
| 12/31/2016 | 23,984 | 806 | N/A | 1,600 | N/A |
| 9/30/2016 | 24,205 | 775 | N/A | 2,175 | N/A |
| 6/30/2016 | 24,794 | 736 | N/A | 2,266 | N/A |
| 3/31/2016 | 26,639 | 688 | N/A | 983 | N/A |
| 12/31/2015 | 27,260 | 761 | N/A | 846 | N/A |
| 9/30/2015 | 24,322 | 711 | N/A | -578 | N/A |
| 6/30/2015 | 21,314 | 646 | N/A | -444 | N/A |
| 3/31/2015 | 17,920 | 701 | N/A | 324 | N/A |
| 12/31/2014 | 15,873 | 701 | N/A | 963 | N/A |
| 9/30/2014 | 15,274 | 676 | N/A | 1,132 | N/A |
| 6/30/2014 | 14,744 | 643 | N/A | 948 | N/A |
| 3/31/2014 | 14,236 | 556 | N/A | 1,170 | N/A |
| 12/31/2013 | 14,272 | 564 | N/A | 1,326 | N/A |
| 9/30/2013 | 14,450 | 625 | N/A | 676 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: 601231's forecast earnings growth (21.7% per year) is above the savings rate (2.9%).
Bénéfices vs marché: 601231's earnings (21.7% per year) are forecast to grow slower than the CN market (21.9% per year).
Croissance élevée des bénéfices: 601231's earnings are expected to grow significantly over the next 3 years.
Chiffre d'affaires vs marché: 601231's revenue (11.4% per year) is forecast to grow slower than the CN market (13.4% per year).
Croissance élevée des revenus: 601231's revenue (11.4% per year) is forecast to grow slower than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: 601231's Return on Equity is forecast to be low in 3 years time (14.6%).